Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat lymphoma: experimental drug surovatamig enters phase 2 trial

NCT ID NCT06526793

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This Phase 2 trial is testing an investigational drug called surovatamig (AZD0486) in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and large B-cell lymphoma. Participants must have tried at least two prior treatments. The study aims to see how well the drug shrinks tumors and how safe it is. About 270 people will take part across multiple centers worldwide.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Surovatamig (AZD0486), an investigational drug given by intravenous infusion
What this could lead to
If successful, this could provide a new treatment option for people with relapsed or refractory B-cell non-Hodgkin lymphoma who have run out of standard therapies.
What could go wrong
This is an early Phase 2 study with no placebo group, so results are preliminary. The drug may cause serious side effects, and not all participants may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Oct 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Key Inclusion Criteria: * Aged 18 years old and above * Histologically confirmed relapsed refractory FL (Module 1) and LBCL (Module 2) after at least 2 prior lines of therapy * ECOG performance status 0 to 2 * Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy * FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as \> 1.5 cm in its longest dimension), or extranodal lesion (defined as \> 1.0 cm in its longest dimension) * Adequate hematological function: ANC ≥ 1000/mm3, platelets * 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening * Adequate liver function: total bilirubin \<1.5x ULN, AST/ALT ≤ 3xULN or \< 5 × ULN in the presence of lymphoma involvement of the liver * Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min * Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA The above is a summary, other inclusion criteria details may apply. 2. Key Exclusion Criteria: * Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation * Active CNS involvement by B-NHL * Leukemic presentation of B-NHL * History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic, or that the treating investigator considers to have the potential to interfere with the evaluation of safety, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, neurodegenerative disorder including Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis or other severe mental illness. * Prior therapy with T-cell engager (TCE) within 8 weeks, autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, CAR T- cell therapy within 6 months, or prior allogeneic HSCT within 24 weeks of first dose of surovatamig * Requires chronic immunosuppressive therapy * Unresolved non hematological AEs ≥ Grade 2 from prior therapies; history of ≥ Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy * History of major cardiac abnormalities. * If female, participant must not be pregnant or breastfeeding. The above is a summary, other exclusion criteria details may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-cell non Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma follicular lymphoma large B-cell lymphoma non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-cell non Hodgkin lymphoma Follicular lymphoma (FL) Large B-cell lymphoma (LBCL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    80 sites in 15 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    WITHDRAWN

    Phoenix, Arizona, 85054, United States

  • Research Site

    RECRUITING

    Duarte, California, 91010, United States

  • Research Site

    WITHDRAWN

    Jacksonville, Florida, 32224, United States

  • Research Site

    RECRUITING

    Tampa, Florida, 33612, United States

  • Research Site

    RECRUITING

    Chicago, Illinois, 60637, United States

  • Research Site

    WITHDRAWN

    Iowa City, Iowa, 52242, United States

  • Research Site

    RECRUITING

    Waukee, Iowa, 50263, United States

  • Research Site

    WITHDRAWN

    Overland Park, Kansas, 66204, United States

  • Research Site

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Research Site

    WITHDRAWN

    St Louis, Missouri, 63110, United States

  • Research Site

    WITHDRAWN

    New Brunswick, New Jersey, 08901, United States

  • Research Site

    RECRUITING

    New York, New York, 10016, United States

  • Research Site

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Research Site

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Research Site

    RECRUITING

    Portland, Oregon, 97239, United States

  • Research Site

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    WITHDRAWN

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Research Site

    RECRUITING

    Austin, Texas, 78704, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    NOT_YET_RECRUITING

    San Antonio, Texas, 78229, United States

  • Research Site

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Research Site

    RECRUITING

    Heidelberg, 3084, Australia

  • Research Site

    RECRUITING

    Kogarah, NSW 2217, Australia

  • Research Site

    RECRUITING

    Macquarie University, 2109, Australia

  • Research Site

    RECRUITING

    Nedlands, 6009, Australia

  • Research Site

    WITHDRAWN

    Porto Alegre, 90035903, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    São Paulo, 01401-002, Brazil

  • Research Site

    ACTIVE_NOT_RECRUITING

    São Paulo, 05652-900, Brazil

  • Research Site

    WITHDRAWN

    Barrie, Ontario, L4M 6M2, Canada

  • Research Site

    RECRUITING

    Brampton, Ontario, L6R 3J7, Canada

  • Research Site

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Site

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    RECRUITING

    Chengdu, 610041, China

  • Research Site

    RECRUITING

    Chengdu, 610072, China

  • Research Site

    RECRUITING

    Guangzhou, 510060, China

  • Research Site

    RECRUITING

    Nanchang, 330029, China

  • Research Site

    RECRUITING

    Nanjing, 210029, China

  • Research Site

    RECRUITING

    Nantong, 226001, China

  • Research Site

    RECRUITING

    Shandong, China

  • Research Site

    RECRUITING

    Shanghai, 200025, China

  • Research Site

    RECRUITING

    Shanghai, 200032, China

  • Research Site

    RECRUITING

    Tianjin, 300020, China

  • Research Site

    RECRUITING

    Zhengzhou, 450008, China

  • Research Site

    WITHDRAWN

    Aalborg, 9100, Denmark

  • Research Site

    RECRUITING

    Copenhagen, 2100, Denmark

  • Research Site

    RECRUITING

    Vejle, 7100, Denmark

  • Research Site

    RECRUITING

    Montpellier, 34295, France

  • Research Site

    RECRUITING

    Paris, 75010, France

  • Research Site

    RECRUITING

    Pierre-Bénite, 69495, France

  • Research Site

    RECRUITING

    Rouen, 76038, France

  • Research Site

    RECRUITING

    Berlin, 10967, Germany

  • Research Site

    RECRUITING

    Chemnitz, 9116, Germany

  • Research Site

    RECRUITING

    Essen, 45147, Germany

  • Research Site

    RECRUITING

    Jena, 07747, Germany

  • Research Site

    RECRUITING

    Würzburg, 97080, Germany

  • Research Site

    RECRUITING

    Hong Kong, 999077, Hong Kong

  • Research Site

    RECRUITING

    Shatin, Hong Kong

  • Research Site

    RECRUITING

    Alessandria, 15121, Italy

  • Research Site

    RECRUITING

    Bologna, 40138, Italy

  • Research Site

    RECRUITING

    Busto Arsizio, 21052, Italy

  • Research Site

    RECRUITING

    Milan, 20132, Italy

  • Research Site

    RECRUITING

    Milan, 20141, Italy

  • Research Site

    WITHDRAWN

    Roma, 161, Italy

  • Research Site

    RECRUITING

    Chiba, 260-8717, Japan

  • Research Site

    RECRUITING

    Kashiwa, 277-8577, Japan

  • Research Site

    RECRUITING

    Kōtoku, 135-8550, Japan

  • Research Site

    RECRUITING

    Kumamoto, 860-0008, Japan

  • Research Site

    RECRUITING

    Niigata, 951-8520, Japan

  • Research Site

    RECRUITING

    Okayama, 700-8558, Japan

  • Research Site

    RECRUITING

    Osaka, 541-8567, Japan

  • Research Site

    RECRUITING

    Yokohama, 241-8515, Japan

  • Research Site

    RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    RECRUITING

    Seoul, 06351, South Korea

  • Research Site

    RECRUITING

    Seoul, 06591, South Korea

  • Research Site

    RECRUITING

    Seoul, 3722, South Korea

  • Research Site

    RECRUITING

    Seoul, 5505, South Korea

  • Research Site

    RECRUITING

    Barcelona, 08035, Spain

  • Research Site

    RECRUITING

    Madrid, 28040, Spain

  • Research Site

    RECRUITING

    Pozuelo de Alarcón, 28223, Spain

  • Research Site

    RECRUITING

    Gothenburg, 41345, Sweden

  • Research Site

    RECRUITING

    Stockholm, 17176, Sweden

  • Research Site

    WITHDRAWN

    Kaohsiung City, 80756, Taiwan

  • Research Site

    RECRUITING

    Kaohsiung City, 833401, Taiwan

  • Research Site

    RECRUITING

    Taichung, 404, Taiwan

  • Research Site

    RECRUITING

    Taichung, 40705, Taiwan

  • Research Site

    RECRUITING

    Tainan, 70403, Taiwan

  • Research Site

    RECRUITING

    Taipei, 106, Taiwan

  • Research Site

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Research Site

    RECRUITING

    Manchester, M20 4BX, United Kingdom

  • Research Site

    RECRUITING

    Norwich, NR4 7UY, United Kingdom

  • Research Site

    RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • Research Site

    RECRUITING

    Plymouth, PL6 8DH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.